Study of genotype frequencies of ANP 664G/A polymorphism in normal subjects and CVD patients, and its association with plasma ANP levels

Atsumi Ohta, Akira Sonoda, Yoko Yatabe, Eiko Takeshita, Ikuo Saito, Daisuke Ito, Norio Tanahashi, Yasuo Fukuuchi, Haruhito Kikuchi, Mitsuru Murata, Kiyoaki Watanabe

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Atrial natriuretic peptide (ANP) plays a crucial role in regulating body fluid volume and blood pressure, by promoting natriuresis and vasodilatation and by inhibiting the renin-angiotensin system. Plasma levels of ANP are elevated in heart failure and hypertension, and ANP is thus believed to be involved in the pathogenesis of cardiovascular disorders. Previous case-control studies have shown that a single nucleotide polymorphism in the first exon of ANP gene, 664G/A, is associated with a risk of cerebrovascular disease (CVD) in white populations. Plasma ANP levels, however, were not evaluated in these studies in relation to the 664G/A, although the nucleotide substitution causes an amino-acid change in the propeptide of ANP. In this study, we analyzed the genotype frequencies of the 664G/A in Japanese patients with CVD (n = 199) and age- and gender-matched control subjects(n = 176). Genotypes with the 664A allele in the Japanese control subjects (G/A and A/A 12.5%) were apparently more frequent compared to the published frequency of the white control population (G/A and A/A 6.6%, p = 0.0437). Genotypes with the 664A allele, however, were not significantly different between our CVD patients(15.1%) and controls (12.5% p = 0.4714). In the control group (n = 137), the mean plasma ANP levels were not different between the 664G/G (15.7 +/- 10.7 pg/ml) and 664G/A genotypes (15.6 +/- 6.8 pg/ml, p = 0.9708). These results suggest that there is a racial difference in the allele frequency of 664G/A, and that this polymorphism may not be a major risk factor for CVD in the Japanese, nor is it a major determinant of plasma ANP level.

Original languageEnglish
Pages (from-to)296-300
Number of pages5
JournalRinsho byori. The Japanese journal of clinical pathology
Volume50
Issue number3
Publication statusPublished - 2002

Fingerprint

Cerebrovascular Disorders
Atrial Natriuretic Factor
Genotype
Alleles
Natriuresis
Body Fluids
Amino Acid Substitution
Renin-Angiotensin System
Gene Frequency
Vasodilation
Population
Single Nucleotide Polymorphism
Case-Control Studies
Exons
Nucleotides
Heart Failure
Blood Pressure
Hypertension
Control Groups

Cite this

Study of genotype frequencies of ANP 664G/A polymorphism in normal subjects and CVD patients, and its association with plasma ANP levels. / Ohta, Atsumi; Sonoda, Akira; Yatabe, Yoko; Takeshita, Eiko; Saito, Ikuo; Ito, Daisuke; Tanahashi, Norio; Fukuuchi, Yasuo; Kikuchi, Haruhito; Murata, Mitsuru; Watanabe, Kiyoaki.

In: Rinsho byori. The Japanese journal of clinical pathology, Vol. 50, No. 3, 2002, p. 296-300.

Research output: Contribution to journalArticle

Ohta, Atsumi ; Sonoda, Akira ; Yatabe, Yoko ; Takeshita, Eiko ; Saito, Ikuo ; Ito, Daisuke ; Tanahashi, Norio ; Fukuuchi, Yasuo ; Kikuchi, Haruhito ; Murata, Mitsuru ; Watanabe, Kiyoaki. / Study of genotype frequencies of ANP 664G/A polymorphism in normal subjects and CVD patients, and its association with plasma ANP levels. In: Rinsho byori. The Japanese journal of clinical pathology. 2002 ; Vol. 50, No. 3. pp. 296-300.
@article{2d3b09c70b014c68a5b5de36d5550b6d,
title = "Study of genotype frequencies of ANP 664G/A polymorphism in normal subjects and CVD patients, and its association with plasma ANP levels",
abstract = "Atrial natriuretic peptide (ANP) plays a crucial role in regulating body fluid volume and blood pressure, by promoting natriuresis and vasodilatation and by inhibiting the renin-angiotensin system. Plasma levels of ANP are elevated in heart failure and hypertension, and ANP is thus believed to be involved in the pathogenesis of cardiovascular disorders. Previous case-control studies have shown that a single nucleotide polymorphism in the first exon of ANP gene, 664G/A, is associated with a risk of cerebrovascular disease (CVD) in white populations. Plasma ANP levels, however, were not evaluated in these studies in relation to the 664G/A, although the nucleotide substitution causes an amino-acid change in the propeptide of ANP. In this study, we analyzed the genotype frequencies of the 664G/A in Japanese patients with CVD (n = 199) and age- and gender-matched control subjects(n = 176). Genotypes with the 664A allele in the Japanese control subjects (G/A and A/A 12.5{\%}) were apparently more frequent compared to the published frequency of the white control population (G/A and A/A 6.6{\%}, p = 0.0437). Genotypes with the 664A allele, however, were not significantly different between our CVD patients(15.1{\%}) and controls (12.5{\%} p = 0.4714). In the control group (n = 137), the mean plasma ANP levels were not different between the 664G/G (15.7 +/- 10.7 pg/ml) and 664G/A genotypes (15.6 +/- 6.8 pg/ml, p = 0.9708). These results suggest that there is a racial difference in the allele frequency of 664G/A, and that this polymorphism may not be a major risk factor for CVD in the Japanese, nor is it a major determinant of plasma ANP level.",
author = "Atsumi Ohta and Akira Sonoda and Yoko Yatabe and Eiko Takeshita and Ikuo Saito and Daisuke Ito and Norio Tanahashi and Yasuo Fukuuchi and Haruhito Kikuchi and Mitsuru Murata and Kiyoaki Watanabe",
year = "2002",
language = "English",
volume = "50",
pages = "296--300",
journal = "Rinsho byori. The Japanese journal of clinical pathology",
issn = "0047-1860",
publisher = "Nihon Rinsho Byori Gakkai",
number = "3",

}

TY - JOUR

T1 - Study of genotype frequencies of ANP 664G/A polymorphism in normal subjects and CVD patients, and its association with plasma ANP levels

AU - Ohta, Atsumi

AU - Sonoda, Akira

AU - Yatabe, Yoko

AU - Takeshita, Eiko

AU - Saito, Ikuo

AU - Ito, Daisuke

AU - Tanahashi, Norio

AU - Fukuuchi, Yasuo

AU - Kikuchi, Haruhito

AU - Murata, Mitsuru

AU - Watanabe, Kiyoaki

PY - 2002

Y1 - 2002

N2 - Atrial natriuretic peptide (ANP) plays a crucial role in regulating body fluid volume and blood pressure, by promoting natriuresis and vasodilatation and by inhibiting the renin-angiotensin system. Plasma levels of ANP are elevated in heart failure and hypertension, and ANP is thus believed to be involved in the pathogenesis of cardiovascular disorders. Previous case-control studies have shown that a single nucleotide polymorphism in the first exon of ANP gene, 664G/A, is associated with a risk of cerebrovascular disease (CVD) in white populations. Plasma ANP levels, however, were not evaluated in these studies in relation to the 664G/A, although the nucleotide substitution causes an amino-acid change in the propeptide of ANP. In this study, we analyzed the genotype frequencies of the 664G/A in Japanese patients with CVD (n = 199) and age- and gender-matched control subjects(n = 176). Genotypes with the 664A allele in the Japanese control subjects (G/A and A/A 12.5%) were apparently more frequent compared to the published frequency of the white control population (G/A and A/A 6.6%, p = 0.0437). Genotypes with the 664A allele, however, were not significantly different between our CVD patients(15.1%) and controls (12.5% p = 0.4714). In the control group (n = 137), the mean plasma ANP levels were not different between the 664G/G (15.7 +/- 10.7 pg/ml) and 664G/A genotypes (15.6 +/- 6.8 pg/ml, p = 0.9708). These results suggest that there is a racial difference in the allele frequency of 664G/A, and that this polymorphism may not be a major risk factor for CVD in the Japanese, nor is it a major determinant of plasma ANP level.

AB - Atrial natriuretic peptide (ANP) plays a crucial role in regulating body fluid volume and blood pressure, by promoting natriuresis and vasodilatation and by inhibiting the renin-angiotensin system. Plasma levels of ANP are elevated in heart failure and hypertension, and ANP is thus believed to be involved in the pathogenesis of cardiovascular disorders. Previous case-control studies have shown that a single nucleotide polymorphism in the first exon of ANP gene, 664G/A, is associated with a risk of cerebrovascular disease (CVD) in white populations. Plasma ANP levels, however, were not evaluated in these studies in relation to the 664G/A, although the nucleotide substitution causes an amino-acid change in the propeptide of ANP. In this study, we analyzed the genotype frequencies of the 664G/A in Japanese patients with CVD (n = 199) and age- and gender-matched control subjects(n = 176). Genotypes with the 664A allele in the Japanese control subjects (G/A and A/A 12.5%) were apparently more frequent compared to the published frequency of the white control population (G/A and A/A 6.6%, p = 0.0437). Genotypes with the 664A allele, however, were not significantly different between our CVD patients(15.1%) and controls (12.5% p = 0.4714). In the control group (n = 137), the mean plasma ANP levels were not different between the 664G/G (15.7 +/- 10.7 pg/ml) and 664G/A genotypes (15.6 +/- 6.8 pg/ml, p = 0.9708). These results suggest that there is a racial difference in the allele frequency of 664G/A, and that this polymorphism may not be a major risk factor for CVD in the Japanese, nor is it a major determinant of plasma ANP level.

UR - http://www.scopus.com/inward/record.url?scp=0036513417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036513417&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 296

EP - 300

JO - Rinsho byori. The Japanese journal of clinical pathology

JF - Rinsho byori. The Japanese journal of clinical pathology

SN - 0047-1860

IS - 3

ER -